Antiseizure medication ≤48 hours portends better prognosis in new‐onset epilepsy
European Journal of Neurology · 2024
DOI: 10.1111/ene.16107 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Eric Ménétré und 8 weiteren Autor:innen. Beteiligte Einrichtung: EEG & Epilepsy Unit, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Epilepsy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Background
Several studies found that patients with new‐onset epilepsy (NOE) have higher seizure recurrence rates if they presented already prior seizures. These observations suggest that timing of antiseizure medication (ASM) is crucial and should be offered immediately after the first seizure. Here, we wanted to assess whether immediate ASM is associated with improved outcome.
Methods
Single‐center study of 1010 patients (≥16 years) who presented with a possible first seizure in the emergency department between 1 March 2010 and 1 March 2017. A comprehensive workup was launched upon arrival, including routine electroencephalography (EEG), brain computed tomography/magnetic resonance imaging, long‐term overnight EEG and specialized consultations. We followed patients for 5 years comparing the relapse rate in patients treated within 48 h to those with treatment >48 h.
Results
A total of 487 patients were diagnosed with NOE. Of the 416 patients (162 female, age: 54.6 ± 21.1 years) for whom the treatment start could be retrieved, 80% (333/416) were treated within 48 h. The recurrence rate after immediate treatment (32%; 107/333) was significantly lower than in patients treated later (56.6%; 47/83; p < 0.001). For patients for whom a complete 5‐year‐follow‐up was available ( N = 297, 123 female), those treated ≤48 h ( N = 228; 76.8%) had a significantly higher chance of remaining seizure‐free compared with patients treated later ( N = 69; 23.2%; p < 0.001).
Conclusions
In this retrospective study, immediate ASM therapy (i.e., within 48 h) was associated with better prognosis up to 5 years after the index event. Prospective studies are required to determine the value of immediate workup and drug therapy in NOE patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EEG & Epilepsy Unit, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland.
- Neuro-Critical Care Unit, Department of Intensive Care, University Hospitals of Geneva, Geneva, Switzerland.
- Division of Emergency Medicine, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
- Neuroradiology Department, University Hospitals of Geneva, Geneva, Switzerland.
ORCID-Profile: Eric Ménétré, Pia De Stefano
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Ménétré, E., De Stefano, P., Megevand, P., Sarasin, F. P., Vargas, M. I., Kleinschmidt, A., Vulliemoz, S., Picard, F., & Seeck, M. (2024). Antiseizure medication ≤48 hours portends better prognosis in new‐onset epilepsy. European Journal of Neurology. https://doi.org/10.1111/ene.16107
Vancouver
Ménétré E, De Stefano P, Megevand P, Sarasin FP, Vargas MI, Kleinschmidt A, et al. Antiseizure medication ≤48 hours portends better prognosis in new‐onset epilepsy. European Journal of Neurology. 2024. doi:10.1111/ene.16107
BibTeX
@article{Mntr2024,
author = {Ménétré, Eric and De Stefano, Pia and Megevand, Pierre and Sarasin, François P and Vargas, Maria I and Kleinschmidt, Andreas and Vulliemoz, Serge and Picard, Fabienne and Seeck, Margitta},
title = {Antiseizure medication ≤48 hours portends better prognosis in new‐onset epilepsy},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16107}
}
EUVIMED